Vericel VCEL NexoBrid — Revenue Not from Contract with Customer, Other
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vericel in its filing.
Tagged under the XBRL concept us-gaap:RevenueNotFromContractWithCustomerOther.
The official record: Vericel’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vericel's nexobrid — revenue not from contract with customer, other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vericel's nexobrid — revenue not from contract with customer, other?
- Vericel (VCEL) reported nexobrid — revenue not from contract with customer, other of $1.14M in Q1 2026.
- How has Vericel's nexobrid — revenue not from contract with customer, other changed year-over-year?
- Vericel's nexobrid — revenue not from contract with customer, other decreased by 14.6% year-over-year, from $1.34M to $1.14M.
- What is the long-term trend for Vericel's nexobrid — revenue not from contract with customer, other?
- Over 4 years (2021 to 2025), Vericel's nexobrid — revenue not from contract with customer, other has grown at a 10.8% compound annual growth rate (CAGR), from $3.11M to $4.69M.
- What does nexobrid — revenue not from contract with customer, other mean?
- This metric represents ancillary revenue streams generated by the NexoBrid product line that fall outside of standard customer sales contracts. It typically includes income from sources such as government grants, research collaborations, or licensing arrangements related to the specific therapeutic asset. Monitoring this figure helps investors assess the diversification of revenue beyond core commercial product sales.